Close Menu

NEW YORK – Recurrence scores from Genomic Health's Oncotype DX test might have a different meaning for men with breast cancer, suggesting a need for a lower cutoff score to predict mortality among male patients, a new study has found.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.